KYTX — Kyverna Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1994702 ·
Last close
$4.70
Market Cap
$297.14M
52W High
$13.67
52W Low
$4.49
ADV30
843,714
Next earnings
2026-11-12
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -42,899,000 -41,941,000 189,437,000 31,818,000 56,283,000
Jun 2026 0 — -39,556,000 -38,319,000 219,823,000 31,806,000 54,274,000
Mar 2026 0 — -41,367,000 -39,728,000 257,024,000 32,194,000 61,444,000
Dec 2025 0 — -39,282,000 -37,804,000 293,826,000 124,093,000 61,550,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-150,797,000
Investing CF
$-2,835,000
Financing CF
$151,286,000
CapEx
$-1,454,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.77
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-544,815,000
Inventory
—
Receivables
—
ST Investments
$138,754,000
EBIT TTM
$-155,279,000
Pretax Income TTM
$-157,792,000
Interest Exp TTM
$2,513,000
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -169,827,000 -161,307,000 293,826,000 61,550,000 232,276,000 -153,712,000
Dec 2024 0 -142,604,000 -127,477,000 304,645,000 38,058,000 266,587,000 -114,250,000
Dec 2023 0 -62,406,000 -60,366,000 75,195,000 206,592,000 -131,397,000 -52,410,000
Dec 2022 7,025,000 -29,384,000 -28,893,000 66,924,000 140,921,000 -73,997,000 -36,113,000

TTM Snapshot

Revenues TTM
$8,161,000
NetIncome TTM
$-152,638,000
OpCashFlow TTM
—
Assets (Latest)
$219,823,000
Forward EPS
$-3.04

Max Pain — expiry 2027-03-19

max pain strike: $7.50 · spot: $4.48 · call oi: 1,176 · put oi: 3,522
Expected Move to 2027-03-19: ±$2.63 (58.71%) — implied range $1.85 – $7.11 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SCTX Scribe Therapeutics, Inc. $298.64M $15.77 —
AGMB AgomAb Therapeutics NV $291.55M $5.92 —
AUTL Autolus Therapeutics plc $290.12M $1.09 —
EDIT Editas Medicine, Inc. $281.67M $1.83 —
AGEN AGENUS INC $280.98M $6.21 —

News headlines (Yahoo Finance, 1h cache)

Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
2026-11-12 13:00 · Yahoo
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
2026-11-09 16:00 · Yahoo
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
2026-11-05 21:02 · Yahoo
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
2026-10-21 11:15 · Yahoo
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
2026-09-24 18:28 · Yahoo
Kyverna stock jumps on positive one-year therapy data
2026-09-24 14:05 · Yahoo
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
2026-09-24 10:39 · Yahoo
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
2026-09-24 10:00 · Yahoo
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-09-02 20:05 · Yahoo
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-09-02 12:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.